Trial Profile
A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary) ; Ustekinumab; Ustekinumab
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms GALAXI; GALAXI 1; GALAXI 2; GALAXI 3
- Sponsors Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Innovative Medicine
- 17 Oct 2023 Results (n=151) assessing clinical, endoscopic, and safety outcomes through 3 years in patients receiving maintenance therapy with GUS in GALAXI-1 long-term extension study presented at the 31st United European Gastroenterology Week
- 17 Oct 2023 Results of post hoc analysis assessing the efficacy of guselkumab in patients with moderately to severely active crohns disease not in Clinical Response at Week 12, presented at the 31st United European Gastroenterology Week.
- 16 Oct 2023 According to Janssen Pharmaceuticals Media Release, data from the study were presented as oral and poster presentations at the United European Gastroenterology (UEGW) Week 2023 taking place in Copenhagen, Denmark, October 14-17, 2023.